The human epidermal growth factor receptor 2 (HER2) is a validated therapeutic target in breast cancer therapy. However, increasing evidence points to a major role for the Δ16HER2 splice variant, which has been identified as a clinically important and tumor-specific HER2 molecular alteration promoting aggressive metastatic breast cancer and conferring resistance to anti-HER2 therapies. Δ16HER2 has an increased transforming potency compared to wild type HER2 receptor, since it promotes constitutive dimerization of the receptor and activation of Src-mediated oncogenic signaling pathways. Consistently, mice transgenic for the human Δ16HER2 isoform (Δ16HER2 mice) develop invasive mammary carcinomas with early onset and 100% penetrance. From...
The transmembrane tyrosine kinase receptor HER2 is overexpressed in about 20% of human breast cancer...
Full-length HER2 oncoprotein and splice variant Delta16 are co-expressed in human breast cancer. We ...
Background: Breast cancer is the most common female malignancy and the leading cause of cancer morta...
The human epidermal growth factor receptor 2 (HER2) is a validated therapeutic target in breast canc...
Almost 90% of human primary breast cancers (BCs) express 4-9% of total wild-type (WT) HER2 as a spli...
HER2 tyrosine kinase receptor is a validated target in breast cancer therapy. However, increasing ev...
HER2 overexpression is a hallmark of aggressive breast cancer subtypes, and HER2-targeted therapies,...
Several transgenic mice models solidly support the hypothesis that HER2 (ERBB2) overexpression or mu...
Breast cancer remains the second leading cause of cancer mortality in women worldwide despite major ...
A splice isoform of the HER2 receptor that lacks exon 16 (d16HER2) is expressed in many HER2-positiv...
A splice isoform of the HER2 receptor that lacks exon 16 (d16HER2) is expressed in many HER2-positiv...
HER-2 is a 185 kDa transmembrane receptor tyrosine kinase that belongs to the EGFR family. HER-2 is ...
We have previously shown that the d16HER2 splice variant is linked to HER2-positive breast cancer (B...
Background: Progress in breast cancer (BC) research relies on the availability of suitable cell line...
Several transgenic mice models solidly support the hypothesis that HER2 (ERBB2) overexpression or mu...
The transmembrane tyrosine kinase receptor HER2 is overexpressed in about 20% of human breast cancer...
Full-length HER2 oncoprotein and splice variant Delta16 are co-expressed in human breast cancer. We ...
Background: Breast cancer is the most common female malignancy and the leading cause of cancer morta...
The human epidermal growth factor receptor 2 (HER2) is a validated therapeutic target in breast canc...
Almost 90% of human primary breast cancers (BCs) express 4-9% of total wild-type (WT) HER2 as a spli...
HER2 tyrosine kinase receptor is a validated target in breast cancer therapy. However, increasing ev...
HER2 overexpression is a hallmark of aggressive breast cancer subtypes, and HER2-targeted therapies,...
Several transgenic mice models solidly support the hypothesis that HER2 (ERBB2) overexpression or mu...
Breast cancer remains the second leading cause of cancer mortality in women worldwide despite major ...
A splice isoform of the HER2 receptor that lacks exon 16 (d16HER2) is expressed in many HER2-positiv...
A splice isoform of the HER2 receptor that lacks exon 16 (d16HER2) is expressed in many HER2-positiv...
HER-2 is a 185 kDa transmembrane receptor tyrosine kinase that belongs to the EGFR family. HER-2 is ...
We have previously shown that the d16HER2 splice variant is linked to HER2-positive breast cancer (B...
Background: Progress in breast cancer (BC) research relies on the availability of suitable cell line...
Several transgenic mice models solidly support the hypothesis that HER2 (ERBB2) overexpression or mu...
The transmembrane tyrosine kinase receptor HER2 is overexpressed in about 20% of human breast cancer...
Full-length HER2 oncoprotein and splice variant Delta16 are co-expressed in human breast cancer. We ...
Background: Breast cancer is the most common female malignancy and the leading cause of cancer morta...